Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma Meeting Abstract
| Authors: | Horwitz, S. M.; Hamadani, M.; Fanale, M. A.; Feingold, J.; Spira, A. I.; Fields, P. A.; Menne, T.; Karnad, A.; Moskowitz, A. J.; Hildyard, C.; He, S.; Boni, J.; Collins, G. |
| Abstract Title: | Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403334 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1510.1510 |
| Notes: | Meeting Abstract: 1510 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work